Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
Crossref DOI link: https://doi.org/10.1186/2051-1426-3-S2-P150
Published Online: 2015-11-04
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ferris, Robert L
Even, Caroline
Haddad, Robert
Tahara, Makoto
Goswami, Trishna
Franks, April
Emeribe, Ugochi
Jarkowski, Anthony
Melillo, Giovanni
Licitra, Lisa
Article History
First Online: 4 November 2015